The EGFRvIII variant in glioblastoma multiforme

Journal of Clinical Neuroscience

Volumn 16, Issue 6, 2009, Pages 748-754

  Gan, Hui K ^a   Kaye, Andrew H ^b   Luwor, Rodney B ^b  

^a PRINCESS MARGARET HOSPITAL   (Canada)

^b UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

EGFRvIII; Glioma; Signalling; Therapy

Indexed keywords

4 (3 CHLOROANILINO) 6,7 DIMETHOXYQUINAZOLINE; CETUXIMAB; CISPLATIN; COLLAGENASE 3; CYCLIN DEPENDENT KINASE INHIBITOR 1B; EPIDERMAL GROWTH FACTOR RECEPTOR 3; EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY; EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY H R3; ERLOTINIB; GEFITINIB; GROWTH FACTOR RECEPTOR BOUND PROTEIN 2; INTERLEUKIN 8; METHOTREXATE; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 425; MONOCLONAL ANTIBODY 528; MONOCLONAL ANTIBODY 806; MONOCLONAL ANTIBODY L8A4; MONOCLONAL ANTIBODY Y10; NSC 154829; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN BCL XL; PROTEIN KINASE B; PROTEIN SHC; PROTEIN TYROSINE KINASE INHIBITOR; RAS PROTEIN; TEMOZOLOMIDE; UNCLASSIFIED DRUG; VASCULOTROPIN;

ADJUVANT THERAPY; CANCER IMMUNOTHERAPY; CANCER INHIBITION; CARCINOGENICITY; CELL PROLIFERATION; CLINICAL TRIAL; DRUG RECEPTOR BINDING; DRUG TARGETING; DRUG TOLERABILITY; GENE AMPLIFICATION; GENE DELETION; GENE MUTATION; GENE REARRANGEMENT; GLIOBLASTOMA; GLIOMA; HUMAN; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN TARGETING; PROTEIN VARIANT; REVIEW; SIGNAL TRANSDUCTION; SINGLE DRUG DOSE; TREATMENT RESPONSE;

ANTIBODIES; ANTINEOPLASTIC AGENTS; BRAIN NEOPLASMS; CELL TRANSFORMATION, NEOPLASTIC; GLIOBLASTOMA; HUMANS; PROTEIN BINDING; PROTEIN STRUCTURE, TERTIARY; RECEPTOR, EPIDERMAL GROWTH FACTOR; SIGNAL TRANSDUCTION; TUMOR MARKERS, BIOLOGICAL;

EID: 67349137902     PISSN: 09675868     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jocn.2008.12.005     Document Type: Review

References (110)

1. Cohen S. Isolation of a mouse submaxillary gland protein accelerating incisor eruption and eyelid opening in the new-born animal. J Biol Chem 237 (1962) 1555-1562
2. Fry D.W. Inhibition of the epidermal growth factor receptor family of tyrosine kinases as an approach to cancer chemotherapy: progression from reversible to irreversible inhibitors. Pharmacol Ther 82 (1999) 207-218
3. Carpenter G., King Jr. L., and Cohen S. Epidermal growth factor stimulates phosphorylation in membrane preparations in vitro. Nature 276 (1978) 409-410
4. Schechter A.L., Stern D.F., Vaidyanathan L., et al. The neu oncogene: an erb-B-related gene encoding a 185, 000-Mr tumour antigen. Nature 312 (1984) 513-516
5. Plowman G.D., Whitney G.S., Neubauer M.G., et al. Molecular cloning and expression of an additional epidermal growth factor receptor-related gene. Proc Natl Acad Sci USA 87 (1990) 4905-4909
6. Plowman G.D., Culouscou J.M., Whitney G.S., et al. Ligand-specific activation of HER4/p180erbB4, a fourth member of the epidermal growth factor receptor family. Proc Natl Acad Sci USA 90 (1993) 1746-1750
7. Olayioye M.A., Neve R.M., Lane H.A., et al. The ErbB signaling network: receptor heterodimerization in development and cancer. Embo J 19 (2000) 3159-3167
8. Riese II D.J., and Stern D.F. Specificity within the EGF family/ErbB receptor family signaling network. Bioessays 20 (1998) 41-48
9. Surawicz T.S., McCarthy B.J., Kupelian V., et al. Descriptive epidemiology of primary brain and CNS tumors: results from the Central Brain Tumor Registry of the United States, 1990-1994. Neuro Oncol 1 (1999) 14-25
10. Kleihues P., Louis D.N., Scheithauer B.W., et al. The WHO classification of tumors of the nervous system. J Neuropathol Exp Neurol 61 (2002) 215-225 discussion 216-219
11. Morokoff A.P., and Novak U. Targeted therapy for malignant gliomas. J Clin Neurosci 11 (2004) 807-818
12. Wong M.L., Kaye A.H., and Hovens C.M. Targeting malignant glioma survival signalling to improve clinical outcomes. J Clin Neurosci 14 (2007) 301-308
13. Ekstrand A.J., James C.D., Cavenee W.K., et al. Genes for epidermal growth factor receptor, transforming growth factor alpha, and epidermal growth factor and their expression in human gliomas in vivo. Cancer Res 51 (1991) 2164-2172
14. Libermann T.A., Razon N., Bartal A.D., et al. Expression of epidermal growth factor receptors in human brain tumors. Cancer Res 44 (1984) 753-760
15. Wong A.J., Ruppert J.M., Bigner S.H., et al. Structural alterations of the epidermal growth factor receptor gene in human gliomas. Proc Natl Acad Sci USA 89 (1992) 2965-2969
16. Ekstrand A.J., Sugawa N., James C.D., et al. Amplified and rearranged epidermal growth factor receptor genes in human glioblastomas reveal deletions of sequences encoding portions of the N- and/or C-terminal tails. Proc Natl Acad Sci USA 89 (1992) 4309-4313
17. Malden L.T., Novak U., Kaye A.H., et al. Selective amplification of the cytoplasmic domain of the epidermal growth factor receptor gene in glioblastoma multiforme. Cancer Res 48 (1988) 2711-2714
18. Sugawa N., Ekstrand A.J., James C.D., et al. Identical splicing of aberrant epidermal growth factor receptor transcripts from amplified rearranged genes in human glioblastomas. Proc Natl Acad Sci USA 87 (1990) 8602-8606
19. Yamazaki H., Fukui Y., Ueyama Y., et al. Amplification of the structurally and functionally altered epidermal growth factor receptor gene (c-erbB) in human brain tumors. Mol Cell Biol 8 (1988) 1816-1820
20. Garcia de Palazzo I.E., Adams G.P., Sundareshan P., et al. Expression of mutated epidermal growth factor receptor by non-small cell lung carcinomas. Cancer Res 53 (1993) 3217-3220
21. Emrich J.G., Brady L.W., Quang T.S., et al. Radioiodinated (I-125) monoclonal antibody 425 in the treatment of high grade glioma patients: ten-year synopsis of a novel treatment. Am J Clin Oncol 25 (2002) 541-546
22. Moscatello D.K., Holgado-Madruga M., Godwin A.K., et al. Frequent expression of a mutant epidermal growth factor receptor in multiple human tumors. Cancer Res 55 (1995) 5536-5539
23. Wikstrand C.J., Hale L.P., Batra S.K., et al. Monoclonal antibodies against EGFRvIII are tumor specific and react with breast and lung carcinomas and malignant gliomas. Cancer Res 55 (1995) 3140-3148
24. Frederick L., Eley G., Wang X.Y., et al. Analysis of genomic rearrangements associated with EGRFvIII expression suggests involvement of Alu repeat elements. Neuro Oncol 2 (2000) 159-163
25. Furnari F.B., Fenton T., Bachoo R.M., et al. Malignant astrocytic glioma: genetics, biology, and paths to treatment. Genes Dev 21 (2007) 2683-2710
26. Downward J., Yarden Y., Mayes E., et al. Close similarity of epidermal growth factor receptor and v-erb-B oncogene protein sequences. Nature 307 (1984) 521-527
27. O'Rourke D.M., Nute E.J., Davis J.G., et al. Inhibition of a naturally occurring EGFR oncoprotein by the p185neu ectodomain: implications for subdomain contributions to receptor assembly. Oncogene 16 (1998) 1197-1207
28. Voldborg B.R., Damstrup L., Spang-Thomsen M., et al. Epidermal growth factor receptor (EGFR) and EGFR mutations, function and possible role in clinical trials. Ann Oncol 8 (1997) 1197-1206
29. Prigent S.A., Nagane M., Lin H., et al. Enhanced tumorigenic behavior of glioblastoma cells expressing a truncated epidermal growth factor receptor is mediated through the Ras-Shc-Grb2 pathway. J Biol Chem 271 (1996) 25639-25645
30. Fernandes H., Cohen S., and Bishayee S. Glycosylation-induced conformational modification positively regulates receptor-receptor association: a study with an aberrant epidermal growth factor receptor (EGFRvIII/DeltaEGFR) expressed in cancer cells. J Biol Chem 276 (2001) 5375-5383
31. Huang H.S., Nagane M., Klingbeil C.K., et al. The enhanced tumorigenic activity of a mutant epidermal growth factor receptor common in human cancers is mediated by threshold levels of constitutive tyrosine phosphorylation and unattenuated signaling. J Biol Chem 272 (1997) 2927-2935
32. Nagane M., Coufal F., Lin H., et al. A common mutant epidermal growth factor receptor confers enhanced tumorigenicity on human glioblastoma cells by increasing proliferation and reducing apoptosis. Cancer Res 56 (1996) 5079-5086
33. Grandal M.V., Zandi R., Pedersen M.W., et al. EGFRvIII escapes down-regulation due to impaired internalization and sorting to lysosomes. Carcinogenesis 28 (2007) 1408-1417
34. Han W., Zhang T., Yu H., et al. Hypophosphorylation of residue Y1045 leads to defective downregulation of EGFRvIII. Cancer Biol Ther 5 (2006) 1361-1368
35. Luwor R.B., Zhu H.J., Walker F., et al. The tumor-specific de2-7 epidermal growth factor receptor (EGFR) promotes cells survival and heterodimerizes with the wild-type EGFR. Oncogene 23 (2004) 6095-6104
36. Montgomery R.B., Guzman J., O'Rourke D.M., et al. Expression of oncogenic epidermal growth factor receptor family kinases induces paclitaxel resistance and alters beta-tubulin isotype expression. J Biol Chem 275 (2000) 17358-17363
37. Ge H., Gong X., and Tang C.K. Evidence of high incidence of EGFRvIII expression and coexpression with EGFR in human invasive breast cancer by laser capture microdissection and immunohistochemical analysis. Int J Cancer 98 (2002) 357-361
38. Al-Nedawi K., Meehan B., Micallef J., et al. Intercellular transfer of the oncogenic receptor EGFRvIII by microvesicles derived from tumour cells. Nat Cell Biol 10 (2008) 619-624
39. Nishikawa R., Ji X.D., Harmon R.C., et al. A mutant epidermal growth factor receptor common in human glioma confers enhanced tumorigenicity. Proc Natl Acad Sci USA 91 (1994) 7727-7731
40. Sugawa N., Yamamoto K., Ueda S., et al. Function of aberrant EGFR in malignant gliomas. Brain Tumor Pathol 15 (1998) 53-57
41. Narita Y., Nagane M., Mishima K., et al. Mutant epidermal growth factor receptor signaling down-regulates p27 through activation of the phosphatidylinositol 3-kinase/Akt pathway in glioblastomas. Cancer Res 62 (2002) 6764-6769
42. Choe G., Horvath S., Cloughesy T.F., et al. Analysis of the phosphatidylinositol 3'-kinase signaling pathway in glioblastoma patients in vivo. Cancer Res 63 (2003) 2742-2746
43. Aldape K.D., Ballman K., Furth A., et al. Immunohistochemical detection of EGFRvIII in high malignancy grade astrocytomas and evaluation of prognostic significance. J Neuropathol Exp Neurol 63 (2004) 700-707
44. Lorimer I.A., and Lavictoire S.J. Activation of extracellular-regulated kinases by normal and mutant EGF receptors. Biochim Biophys Acta 1538 (2001) 1-9
45. Mizoguchi M., Betensky R.A., Batchelor T.T., et al. Activation of STAT3, MAPK, and AKT in malignant astrocytic gliomas: correlation with EGFR status, tumor grade, and survival. J Neuropathol Exp Neurol 65 (2006) 1181-1188
46. Pedersen M.W., Pedersen N., Damstrup L., et al. Analysis of the epidermal growth factor receptor specific transcriptome: effect of receptor expression level and an activating mutation. J Cell Biochem 96 (2005) 412-427
47. Huang P.H., Mukasa A., Bonavia R., et al. Quantitative analysis of EGFRvIII cellular signaling networks reveals a combinatorial therapeutic strategy for glioblastoma. Proc Natl Acad Sci USA 104 (2007) 12867-12872
48. Klingler-Hoffmann M., Bukczynska P., and Tiganis T. Inhibition of phosphatidylinositol 3-kinase signaling negates the growth advantage imparted by a mutant epidermal growth factor receptor on human glioblastoma cells. Int J Cancer 105 (2003) 331-339
49. Horvath S., Zhang B., Carlson M., et al. Analysis of oncogenic signaling networks in glioblastoma identifies ASPM as a molecular target. Proc Natl Acad Sci USA 103 (2006) 17402-17407
50. Boise L.H., Gonzalez-Garcia M., Postema C.E., et al. Bcl-x, a bcl-2-related gene that functions as a dominant regulator of apoptotic cell death. Cell 74 (1993) 597-608
51. Mishima K., Johns T.G., Luwor R.B., et al. Growth suppression of intracranial xenografted glioblastomas overexpressing mutant epidermal growth factor receptors by systemic administration of monoclonal antibody (mAb) 806, a novel monoclonal antibody directed to the receptor. Cancer Res 61 (2001) 5349-5354
52. Nagane M., Levitzki A., Gazit A., et al. Drug resistance of human glioblastoma cells conferred by a tumor-specific mutant epidermal growth factor receptor through modulation of Bcl-XL and caspase-3-like proteases. Proc Natl Acad Sci USA 95 (1998) 5724-5729
53. Nagane M., Narita Y., Mishima K., et al. Human glioblastoma xenografts overexpressing a tumor-specific mutant epidermal growth factor receptor sensitized to cisplatin by the AG1478 tyrosine kinase inhibitor. J Neurosurg 95 (2001) 472-479
54. Lal A., Glazer C.A., Martinson H.M., et al. Mutant epidermal growth factor receptor up-regulates molecular effectors of tumor invasion. Cancer Res 62 (2002) 3335-3339
55. Wu J.L., Abe T., Inoue R., et al. IkappaBalphaM suppresses angiogenesis and tumorigenesis promoted by a constitutively active mutant EGFR in human glioma cells. Neurol Res 26 (2004) 785-791
56. Jungbluth A.A., Stockert E., Huang H.J., et al. A monoclonal antibody recognizing human cancers with amplification/overexpression of the human epidermal growth factor receptor. Proc Natl Acad Sci USA 100 (2003) 639-644
57. Lorimer I.A., Keppler-Hafkemeyer A., Beers R.A., et al. Recombinant immunotoxins specific for a mutant epidermal growth factor receptor: targeting with a single chain antibody variable domain isolated by phage display. Proc Natl Acad Sci USA 93 (1996) 14815-14820
58. Archer G.E., Sampson J.H., Lorimer I.A., et al. Regional treatment of epidermal growth factor receptor vIII-expressing neoplastic meningitis with a single-chain immunotoxin, MR-1. Clin Cancer Res 5 (1999) 2646-2652
59. Patel D., Lahiji A., Patel S., et al. Monoclonal antibody cetuximab binds to and down-regulates constitutively activated epidermal growth factor receptor vIII on the cell surface. Anticancer Res 27 (2007) 3355-3366
60. Wu G., Yang W., Barth R.F., et al. Molecular targeting and treatment of an epidermal growth factor receptor-positive glioma using boronated cetuximab. Clin Cancer Res 13 (2007) 1260-1268
61. Yang W., Wu G., Barth R.F., et al. Molecular targeting and treatment of composite EGFR and EGFRvIII-positive gliomas using boronated monoclonal antibodies. Clin Cancer Res 14 (2008) 883-891
62. Johns T.G., Perera R.M., Vernes S.C., et al. The efficacy of epidermal growth factor receptor-specific antibodies against glioma xenografts is influenced by receptor levels, activation status, and heterodimerization. Clin Cancer Res 13 (2007) 1911-1925
63. Sampson J.H., Crotty L.E., Lee S., et al. Unarmed, tumor-specific monoclonal antibody effectively treats brain tumors. Proc Natl Acad Sci USA 97 (2000) 7503-7508
64. Yang W., Barth R.F., Wu G., et al. Molecular targeting and treatment of EGFRvIII-positive gliomas using boronated monoclonal antibody L8A4. Clin Cancer Res 12 (2006) 3792-3802
65. Johns T.G., Stockert E., Ritter G., et al. Novel monoclonal antibody specific for the de2-7 epidermal growth factor receptor (EGFR) that also recognizes the EGFR expressed in cells containing amplification of the EGFR gene. Int J Cancer 98 (2002) 398-408
66. Johns T.G., Luwor R.B., Murone C., et al. Antitumor efficacy of cytotoxic drugs and the monoclonal antibody 806 is enhanced by the EGF receptor inhibitor AG1478. Proc Natl Acad Sci USA 100 (2003) 15871-15876
67. Johns T.G., Adams T.E., Cochran J.R., et al. Identification of the epitope for the epidermal growth factor receptor-specific monoclonal antibody 806 reveals that it preferentially recognizes an untethered form of the receptor. J Biol Chem 279 (2004) 30375-30384
68. Luwor R.B., Johns T.G., Murone C., et al. Monoclonal antibody 806 inhibits the growth of tumor xenografts expressing either the de2-7 or amplified epidermal growth factor receptor (EGFR) but not wild-type EGFR. Cancer Res 61 (2001) 5355-5361
69. Perera R.M., Narita Y., Furnari F.B., et al. Treatment of human tumor xenografts with monoclonal antibody 806 in combination with a prototypical epidermal growth factor receptor-specific antibody generates enhanced antitumor activity. Clin Cancer Res 11 (2005) 6390-6399
70. Cemeus C., Zhao T.T., Barrett G.M., et al. Lovastatin enhances gefitinib activity in glioblastoma cells irrespective of EGFRvIII and PTEN status. J Neurooncol 90 (2008) 9-17
71. Heimberger A.B., Learn C.A., Archer G.E., et al. Brain tumors in mice are susceptible to blockade of epidermal growth factor receptor (EGFR) with the oral, specific, EGFR-tyrosine kinase inhibitor ZD1839 (iressa). Clin Cancer Res 8 (2002) 3496-3502
72. Learn C.A., Hartzell T.L., Wikstrand C.J., et al. Resistance to tyrosine kinase inhibition by mutant epidermal growth factor receptor variant III contributes to the neoplastic phenotype of glioblastoma multiforme. Clin Cancer Res 10 (2004) 3216-3224
73. Wang M.Y., Lu K.V., Zhu S., et al. Mammalian target of rapamycin inhibition promotes response to epidermal growth factor receptor kinase inhibitors in PTEN-deficient and PTEN-intact glioblastoma cells. Cancer Res 66 (2006) 7864-7869
74. Mellinghoff I.K., Wang M.Y., Vivanco I., et al. Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors. N Engl J Med 353 (2005) 2012-2024
75. Marie Y., Carpentier A.F., Omuro A.M., et al. EGFR tyrosine kinase domain mutations in human gliomas. Neurology 64 (2005) 1444-1445
76. Rich J.N., Rasheed B.K., and Yan H. EGFR mutations and sensitivity to gefitinib. N Engl J Med 351 (2004) 1260-1261 author reply 1260-1261
77. Levitzki A., and Gazit A. Tyrosine kinase inhibition: an approach to drug development. Science 267 (1995) 1782-1788
78. Trembath D.G., Lal A., Kroll D.J., et al. A novel small molecule that selectively inhibits glioblastoma cells expressing EGFRvIII. Mol Cancer 6 (2007) 30
79. Heimberger A.B., Crotty L.E., Archer G.E., et al. Epidermal growth factor receptor VIII peptide vaccination is efficacious against established intracerebral tumors. Clin Cancer Res 9 (2003) 4247-4254
80. Moscatello D.K., Ramirez G., and Wong A.J. A naturally occurring mutant human epidermal growth factor receptor as a target for peptide vaccine immunotherapy of tumors. Cancer Res 57 (1997) 1419-1424
81. Sampson J.H., Archer G.E., Mitchell D.A., et al. Tumor-specific immunotherapy targeting the EGFRvIII mutation in patients with malignant glioma. Semin Immunol 20 (2008) 267-275
82. Franceschi E., Cavallo G., Lonardi S., et al. Gefitinib in patients with progressive high-grade gliomas: a multicentre phase II study by Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO). Br J Cancer 96 (2007) 1047-1051
83. Omuro A.M., Faivre S., and Raymond E. Lessons learned in the development of targeted therapy for malignant gliomas. Mol Cancer Ther 6 (2007) 1909-1919
84. Rich J.N., Reardon D.A., Peery T., et al. Phase II trial of gefitinib in recurrent glioblastoma. J Clin Oncol 22 (2004) 133-142
85. Stommel J.M., Kimmelman A.C., Ying H., et al. Coactivation of receptor tyrosine kinases affects the response of tumor cells to targeted therapies. Science 318 (2007) 287-290
86. Lieberman F.S., Cloughesy T., Fine H., et al. NABTC phase I/II trial of ZD-1839 for recurrent malignant gliomas and unresectable meningiomas. J Clin Oncol, 2004 ASCO Annual Meeting Proceedings 22 (2004) 1510
87. Cloughesy T., Yung A., Vrendenberg J., et al. Phase II study of erlotinib in recurrent GBM: molecular predictors of outcome. J Clin Oncol, 2005 ASCO Annual Meeting Proceedings 23 (2005) 1507
88. Raizer J.J., Abrey L.E., Wen P., et al. A Phase II trial of erlotinib (OSI-774) in patients (pts) with recurrent malignant gliomas (MG) not on EIAED's. J Clin Oncol, 2004 ASCO Annual Meeting Proceedings 22 (2004) 1502
89. Vogelbaum M.A., Peereboom D., Stevens G., et al. Phase II trial of the EGFR tyrosine Kinase Inhibitor erlotinib for single agent therapy of recurrent Glioblastoma Multiforme: interim results. J Clin Oncol, 2004 ASCO Annual Meeting Proceedings 22 (2004) 1558
90. Neyns B., Sadones J., Joosens E., et al. A multicenter stratified phase II study of cetuximab for the treatment of patients with recurrent high-grade glioma. J Clin Oncol, 2008 ASCO Annual Meeting Proceedings 26 (2008) 2017
91. Ramos T.C., Figueredo J., Catala M., et al. Treatment of high-grade glioma patients with the humanized anti-epidermal growth factor receptor (EGFR) antibody h-R3: report from a phase I/II trial. Cancer Biol Ther 5 (2006) 375-379
92. Brady L.W., Miyamoto C., Woo D.V., et al. Malignant astrocytomas treated with iodine-125 labeled monoclonal antibody 425 against epidermal growth factor receptor: a phase II trial. Int J Radiat Oncol Biol Phys 22 (1992) 225-230
93. Wygoda Z., Kula D., Bierzynska-Macyszyn G., et al. Use of monoclonal anti-EGFR antibody in the radioimmunotherapy of malignant gliomas in the context of EGFR expression in grade III and IV tumors. Hybridoma (Larchmt) 25 (2006) 125-132
94. Scott A.M., Lee F.T., Tebbutt N., et al. A phase I clinical trial with monoclonal antibody ch806 targeting transitional state and mutant epidermal growth factor receptors. Proc Natl Acad Sci USA 104 (2007) 4071-4076
95. Li G., and Wong A.J. EGF receptor variant III as a target antigen for tumor immunotherapy. Expert Rev Vaccines 7 (2008) 977-985
96. Bigner S.H., Humphrey P.A., Wong A.J., et al. Characterization of the epidermal growth factor receptor in human glioma cell lines and xenografts. Cancer Res 50 (1990) 8017-8022
97. Filmus J., Pollak M.N., Cairncross J.G., et al. Amplified, overexpressed and rearranged epidermal growth factor receptor gene in a human astrocytoma cell line. Biochem Biophys Res Commun 131 (1985) 207-215
98. Feldkamp M.M., Lala P., Lau N., et al. Expression of activated epidermal growth factor receptors, Ras-guanosine triphosphate, and mitogen-activated protein kinase in human glioblastoma multiforme specimens. Neurosurgery 45 (1999) 1442-1453
99. Heimberger A.B., Hlatky R., Suki D., et al. Prognostic effect of epidermal growth factor receptor and EGFRvIII in glioblastoma multiforme patients. Clin Cancer Res 11 (2005) 1462-1466
100. Liu L., Backlund L.M., Nilsson B.R., et al. Clinical significance of EGFR amplification and the aberrant EGFRvIII transcript in conventionally treated astrocytic gliomas. J Mol Med 83 (2005) 917-926
101. Pelloski C.E., Ballman K.V., Furth A.F., et al. Epidermal growth factor receptor variant III status defines clinically distinct subtypes of glioblastoma. J Clin Oncol 25 (2007) 2288-2294
102. Omuro A.M. What is the relevance of determining EGFR-variant-III status in glioblastomas?. Nat Clin Pract Oncol 5 (2008) 188-189
103. Shinojima N., Tada K., Shiraishi S., et al. Prognostic value of epidermal growth factor receptor in patients with glioblastoma multiforme. Cancer Res 63 (2003) 6962-6970
104. Haas-Kogan D.A., Prados M.D., Tihan T., et al. Epidermal growth factor receptor, protein kinase B/Akt, and glioma response to erlotinib. J Natl Cancer Inst 97 (2005) 880-887
105. D'Abaco G.M., and Kaye A.H. Integrins: molecular determinants of glioma invasion. J Clin Neurosci 14 (2007) 1041-1048
106. Soni D., King J.A., Kaye A.H., et al. Genetics of glioblastoma multiforme: mitogenic signaling and cell cycle pathways converge. J Clin Neurosci 12 (2005) 1-5
107. Wen P.Y., and Kesari S. Malignant gliomas in adults. N Engl J Med 359 (2008) 492-507
108. Batchelor T.T., Sorensen A.G., di Tomaso E., et al. AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. Cancer Cell 11 (2007) 83-95
109. Sathornsumetee S., Vredenburgh J.J., Rich J.N., et al. Phase II study of bevacizumab and erlotinib in patients with recurrent glioblastoma multiforme. J Clin Oncol, 2008 ASCO Annual Meeting Proceedings 26 (2008) 13008
110. Robins H.I., Wen P.Y., Chang S.M., et al. Phase I study of erlotinib and CCI-779 (temsirolimus) for patients with recurrent malignant gliomas (MG) (NABTC 04-02). J Clin Oncol, 2007 ASCO Annual Meeting Proceedings 25 (2007) 2057